1
|
Khairnar P, Saathoff JM, Cook DW, Hochstetler SR, Pandya U, Robinson SJ, Satam V, Donsbach KO, Gupton BF, Jin LM, Shanahan CS. Practical Synthesis of 6-Amino-1-hydroxy-2,1-benzoxaborolane: A Key Intermediate of DNDI-6148. Org Process Res Dev 2024; 28:1213-1223. [PMID: 38660377 PMCID: PMC11036395 DOI: 10.1021/acs.oprd.4c00031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Revised: 03/03/2024] [Accepted: 03/11/2024] [Indexed: 04/26/2024]
Abstract
Visceral leishmaniasis (VL), a parasitic, poverty-linked, neglected disease, is endemic across multiple regions of the world and fatal if untreated. There is an urgent need for a better and more affordable treatment for VL. DNDI-6148 is a promising drug candidate being evaluated for the treatment of VL; however, the current process for producing the key intermediate of DNDI-6148, 6-amino-1-hydroxy-2,1-benzoxaborolane, is expensive and difficult to scale up. Herein, we describe two practical approaches to synthesizing 6-amino-1-hydroxy-2,1-benzoxaborolane from inexpensive and readily available raw materials. Starting with 4-tolunitrile, the first approach is a five-step sequence involving a Hofmann rearrangement, resulting in an overall yield of 40%. The second approach utilizes 2-methyl-5-nitroaniline as the starting material and features borylation of aniline and continuous flow hydrogenation as the key steps, with an overall yield of 46%. Both routes bypass the nitration of 1-hydroxy-2,1-benzoxaborolane, which is challenging and expensive to scale. In particular, the second approach is more practical and scalable because of the mild operating conditions and facile isolation process.
Collapse
Affiliation(s)
- Pankaj
V. Khairnar
- Medicines
for All Institute, Virginia Commonwealth
University, Richmond, Virginia 23284-3068, United States
| | - John M. Saathoff
- Medicines
for All Institute, Virginia Commonwealth
University, Richmond, Virginia 23284-3068, United States
| | - Daniel W. Cook
- Medicines
for All Institute, Virginia Commonwealth
University, Richmond, Virginia 23284-3068, United States
| | - Samuel R. Hochstetler
- Medicines
for All Institute, Virginia Commonwealth
University, Richmond, Virginia 23284-3068, United States
| | - Urvish Pandya
- Drugs
for Neglected Diseases initiative, 15 Chemin Camille-Vidart, 1202 Geneva, Switzerland
| | - Stephen J. Robinson
- Drugs
for Neglected Diseases initiative, 15 Chemin Camille-Vidart, 1202 Geneva, Switzerland
| | - Vijay Satam
- Drugs
for Neglected Diseases initiative, 15 Chemin Camille-Vidart, 1202 Geneva, Switzerland
| | - Kai O. Donsbach
- Medicines
for All Institute, Virginia Commonwealth
University, Richmond, Virginia 23284-3068, United States
| | - B. Frank Gupton
- Medicines
for All Institute, Virginia Commonwealth
University, Richmond, Virginia 23284-3068, United States
| | - Li-Mei Jin
- Medicines
for All Institute, Virginia Commonwealth
University, Richmond, Virginia 23284-3068, United States
| | - Charles S. Shanahan
- Medicines
for All Institute, Virginia Commonwealth
University, Richmond, Virginia 23284-3068, United States
| |
Collapse
|
2
|
Fischer G. The chemistry of citrazinic acid (2,6-dihydroxyisonicotinic acid). ADVANCES IN HETEROCYCLIC CHEMISTRY 2023. [DOI: 10.1016/bs.aihch.2022.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
4
|
Schäfer G, Ahmetovic M, Fleischer T, Abele S. Development of a Scalable Route for a Highly Polar Heterocyclic Aminocyclopropyl Building Block. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00358] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Gabriel Schäfer
- Chemistry Process R&D, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Muhamed Ahmetovic
- Chemistry Process R&D, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Tony Fleischer
- Chemistry Process R&D, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Stefan Abele
- Chemistry Process R&D, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| |
Collapse
|
5
|
Connor CG, DeForest JC, Dietrich P, Do NM, Doyle KM, Eisenbeis S, Greenberg E, Griffin SH, Jones BP, Jones KN, Karmilowicz M, Kumar R, Lewis CA, McInturff EL, McWilliams JC, Mehta R, Nguyen BD, Rane AM, Samas B, Sitter BJ, Ward HW, Webster ME. Development of a Nitrene-Type Rearrangement for the Commercial Route of the JAK1 Inhibitor Abrocitinib. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00366] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
6
|
Meng Z, Huang Y, Cheng S, Wang J. Investigation of Oiling‐Out Phenomenon of Small Organic Molecules in Crystallization Processes: A Review. ChemistrySelect 2020. [DOI: 10.1002/slct.202001255] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Zichao Meng
- School of Chemical Engineering and TechnologyTianjin University No. 92 Weijin Road Tianjin 300072 P.R. China
| | - Yan Huang
- School of Chemical Engineering and TechnologyTianjin University No. 92 Weijin Road Tianjin 300072 P.R. China
| | - Shuo Cheng
- School of Chemical Engineering and TechnologyTianjin University No. 92 Weijin Road Tianjin 300072 P.R. China
| | - Jingtao Wang
- School of Chemical Engineering and TechnologyTianjin University No. 92 Weijin Road Tianjin 300072 P.R. China
| |
Collapse
|